Population Health Sciences

You are here

Publications

Found 57 results
Author Title Type [ Year(Asc)]
Filters: First Letter Of Title is P  [Clear All Filters]
2020
Meinhofer A.  2020.  Pediatric Implications of Opioid-Specific Parental Drug Use-Reply.. JAMA Pediatr.
Mullangi S, Bhandari R, Thanaporn P, Christensen M, Kronick S, Nallamothu BK.  2020.  Perceptions of resuscitation care among in-hospital cardiac arrest responders: a qualitative analysis.. BMC Health Serv Res. 20(1):145.
Batra JS, Niaz MJunaid, Whang YE, Sheikh A, Thomas C, Christos P, Vallabhajosula S, Jhanwar YS, Molina AM, Nanus DM et al..  2020.  Phase I trial of docetaxel plus lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (Lu-J591) for metastatic castration-resistant prostate cancer.. Urol Oncol.
Chaabane S, Chaabna K, Abraham A, Mamtani R, Cheema S.  2020.  Physical activity and sedentary behaviour in the Middle East and North Africa: An overview of systematic reviews and meta-analysis.. Sci Rep. 10(1):9363.
Ponirakis G, Elhadd T, Chinnaiyan S, Dabbous Z, Siddiqui M, Al-Muhannadi H, Petropoulos IN, Khan A, Ashawesh KAE, Dukhan KMO et al..  2020.  Prevalence and management of diabetic neuropathy in secondary care in Qatar.. Diabetes Metab Res Rev. 36(4):e3286.
Ponirakis G, Elhadd T, Chinnaiyan S, Dabbous Z, Siddiqui M, Al-Muhannadi H, Petropoulos IN, Khan A, Ashawesh KAE, Dukhan KMO et al..  2020.  Prevalence and management of diabetic neuropathy in secondary care in Qatar.. Diabetes Metab Res Rev. 36(4):e3286.
Shoag J, Liu D, Ma X, Oromendia C, Christos P, Ballman K, Angulo C, Cai PY, Gaffney C, Klein E et al..  2020.  Prognostic value of the SPOP mutant genomic subclass in prostate cancer.. Urol Oncol.
Frey MK, Kahn RM, Chapman-Davis E, Tubito F, Pires M, Christos P, Anderson S, Mukherjee S, Jordan B, Blank SV et al..  2020.  Prospective Feasibility Trial of a Novel Strategy of Facilitated Cascade Genetic Testing Using Telephone Counseling.. J Clin Oncol. 38(13):1389-1397.
Xie Y, Valdimarsdóttir UA, Wang C, Zhong XR, Gou Q, Zheng H, Deng L, He P, Hu K, Fall K et al..  2020.  Public health insurance and cancer-specific mortality risk among patients with breast cancer: A prospective cohort study in China.. Int J Cancer.
Barfield E, Deshmukh F, Slighton E, Lentine J, Lu Y, Ma X, Christos PJ, Sockolow RE, Loughlin G, Pillai S.  2020.  Pulmonary Manifestations in Adolescents With Inflammatory Bowel Disease.. Clin Pediatr (Phila). :9922820910821.
2019
Khullar D, Wolfson D, Casalino LP.  2019.  Patient-Centered Performance Metrics-Reply.. JAMA. 321(18):1829-1830.
Martin P, Bartlett NL, Blum KA, Park S, Maddocks K, Ruan J, Ridling LA, Dittus C, Chen Z, Huang X et al..  2019.  A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma.. Blood. 133(11):1201-1204.
Tagawa ST, Vallabhajosula S, Christos PJ, Jhanwar YS, Batra JS, Lam L, Osborne J, Beltran H, Molina AM, Goldsmith SJ et al..  2019.  Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 ( Lu-J591) for metastatic castration-resistant prostate cancer.. Cancer. 125(15):2561-2569.
Martin P, Ruan J, Furman R, Rutherford S, Allan J, Chen Z, Huang X, DiLiberto M, Chen-Kiang S, Leonard JP.  2019.  A phase I trial of palbociclib plus bortezomib in previously treated mantle cell lymphoma.. Leuk Lymphoma. :1-5.
Beltran H, Oromendia C, Danila DC, Montgomery B, Hoimes C, Szmulewitz RZ, Vaishampayan U, Armstrong AJ, Stein M, Pinski J et al..  2019.  A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.. Clin Cancer Res. 25(1):43-51.
Lazow SP, Venn RA, Lubor B, Kocharian G, Kreines FM, Gilbert E, Marnell CS, Cricco-Lizza E, Cooley V, Christos P et al..  2019.  The PreOp Program: Intensive Preclinical Surgical Exposure is Associated With Increased Medical Student Surgical Interest and Competency.. J Surg Educ.
Meinhofer A, Williams ARobin, Johnson P, Schackman BR, Bao Y.  2019.  Prescribing decisions at buprenorphine treatment initiation: Do they matter for treatment discontinuation and adverse opioid-related events? J Subst Abuse Treat. 105:37-43.
Wen H, Hockenberry JM, Jeng PJ, Bao Y.  2019.  Prescription Drug Monitoring Program Mandates: Impact On Opioid Prescribing And Related Hospital Use.. Health Aff (Millwood). 38(9):1550-1556.
Kapadia SN, Bao Y.  2019.  Prescription painkiller misuse and the perceived risk of harm from using heroin.. Addict Behav. 93:141-145.
Kennel PJ, Kneifati-Hayek J, Bryan J, Banerjee S, Sobol I, Lachs MS, Safford MM, Goyal P.  2019.  Prevalence and determinants of Hyperpolypharmacy in adults with heart failure: an observational study from the National Health and Nutrition Examination Survey (NHANES).. BMC Cardiovasc Disord. 19(1):76.